Latest News-Telix Pharmaceuticals Corporate Limited Mediaroom_Page

Telix Successfully Prices A$650 Million Convertible Bonds

MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix...

2024-07-24 07:51 1904

Telix Announces A$600 Million Convertible Bonds Offering

MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix...

2024-07-23 16:35 1802

Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade

MELBOURNE, Australia, July 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-07-18 07:17 2059

Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals

MELBOURNE, Australia, July 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-07-11 08:21 1920

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, ...

2024-06-03 09:08 1599

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

* TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being de...

2024-05-31 07:19 2070

Telix Submits NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, ...

2024-05-27 07:21 1940

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

* CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based...

2024-05-21 07:58 1544

Q1 2024 Revenue and Business Update

MELBOURNE, Australia, April 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2024-04-17 15:05 2046

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

* FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging * Collabo...

2024-04-16 06:42 1446

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Te...

2024-03-27 05:59 956

QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy

MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Lim...

2024-03-19 05:19 1916

Appointment of Dr Darren Patti to Group Chief Operating Officer

MELBOURNE, Australia, March 12, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2024-03-12 05:44 1909

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-03-05 07:01 1751

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

MELBOURNE, Australia, Feb. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-02-27 05:55 8220

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

MELBOURNE, Australia, Feb. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-02-22 17:31 2322

Latest News